Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03408470
Other study ID # 0152
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date January 31, 2018
Est. completion date February 21, 2018

Study information

Verified date January 2021
Source Theravance Biopharma
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label, 2-cohort study to evaluate the absolute bioavailability, absorption, distribution, metabolism and excretion of TD-1473 in healthy male subjects. Subjects in cohort 1 will receive a single oral dose of TD-1473 and a single intravenous bolus dose of [14C]-TD-1473. Subjects in cohort 2 will receive a single oral dose of [14C]-TD-1473 only.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date February 21, 2018
Est. primary completion date February 21, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 19 Years to 55 Years
Eligibility Inclusion Criteria: - Subject is a healthy, nonsmoking male, 19 to 55 years old, inclusive - Subject has a body mass index (BMI) 19 to 32 kg/m2, inclusive, and weighs at least 50 kg - Subject is healthy as determined by the PI or designee based on medical history and physical examination performed at Screening and Day -1 - Additional inclusion criteria apply Exclusion Criteria: - Subject has any condition possibly affecting drug absorption (e.g., previous surgery on the gastrointestinal tract [including removal of parts of the stomach, bowel, liver, gall bladder, or pancreas]) - Subject has a known hypersensitivity towards medications similar to TD 1473 or excipients contained in TD 1473 - Subject regularly works with ionizing radiation or radioactive material - Subject has been exposed to ionizing radiations, within 1 year prior to the start of the study, as external irradiation (i.e., radiological examination including CT scan, excluding dental radiography) or internal radiation (i.e., diagnostic nuclear medicine procedure) or have participated in a radiolabeled study in the last 12 months - Subject, who, for any reason, is deemed by the PI or designee or Sponsor to be inappropriate for this study or have any condition which would confound or interfere with the evaluation of the safety, tolerability, and PK of the investigational drug or prevent compliance with the study protocol - Additional exclusion criteria apply

Study Design


Intervention

Drug:
TD-1473 oral capsule
(Intervention description included in arm description)
[14C]-TD-1473 IV bolus
(Intervention description included in arm description)
[14C]-TD-1473 Oral Capsule
(Intervention description included in arm description)

Locations

Country Name City State
United States Celerion Lincoln Nebraska

Sponsors (1)

Lead Sponsor Collaborator
Theravance Biopharma

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Metabolites in Plasma TD 1473 metabolite profiling will be performed in plasma containing sufficient amounts of radioactivity Up to 15 days
Other Metabolites in Urine TD 1473 metabolite profiling will be performed in urine containing sufficient amounts of radioactivity Up to 15 days
Other Metabolites in Feces TD-1473 metabolite profiling will be performed in feces containing sufficient amounts of radioactivity Up to 15 days
Primary Maximum observed concentration (Cmax) in Plasma Up to 15 days
Primary Time to maximum observed concentration (tmax) in Plasma Up to 15 days
Primary Area under the concentration-time curve from hour 0 to the last measurable concentration (AUC0-last) in Plasma Up to 15 days
Primary Area under the concentration-time curve extrapolated to infinity (AUC0-inf) in Plasma Up to 15 days
Primary Apparent terminal elimination half-life (t1/2) in Plasma Up to 15 days
Primary Apparent clearance (Cl/F) in Plasma Up to 15 days
Primary Apparent volume of distribution (Vz/F) in Plasma Up to 15 days
Primary Absolute bioavailability (%F) in Plasma Up to 15 days
Secondary Amount excreted in urine (Aeu) over the sampling interval in Urine Up to 15 days
Secondary Renal clearance (CLr) in Urine Up to 15 days
Secondary The percent excreted in urine (%Feu) in Urine Up to 15 days
Secondary Amount excreted in feces (Aef) over the sampling interval in Feces Up to 15 days
Secondary The percent excreted in feces (%Fef) Up to 15 days
See also
  Status Clinical Trial Phase
Completed NCT00640809 - Comparison of Small Bowel Lesions Associated With Celecoxib Versus Ibuprofen Plus Omeprazole Phase 4
Completed NCT04587713 - Single Dose Bioavailability and Ethnobridging PK Study in Healthy Subjects Phase 1
Completed NCT05043363 - LuCID - Investigating the Use of a Novel Digital Rectoscope for Community Examinations During COVID-19
Completed NCT02799615 - Anti-TNF Therapy for Refractory Colitis in Hospitalized Children
Not yet recruiting NCT02760940 - Anemia in Inflammatory Bowel Disease Phase 4
Terminated NCT04032756 - Tofacitinib Registry of Patients With Ulcerative Colitis in Germany
Terminated NCT02255227 - Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for CIBD Phase 2
Completed NCT03999294 - Bmgim Music Therapy Method in Reducing Stress in Patients With Inflammatory Bowel Disease N/A